Lynk Pharmaceuticals Lynk Pharmaceuticals (also known as 凌科药业) is a biotech company engaged in the research and development of medicines to treat autoimmune and inflammation diseases, as well as cancer. | Rigel Pharmaceuticals Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases. | ![]() BridgeBio BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases. | |
Founding Date | Founding Date 2018 | Founding Date 1996 | Founding Date 2014 |
Type | Type Private | Type Public | Type Public |
Tags | |||
Locations | Locations Hang Zhou Shi, CN HQ | Locations South San Francisco, US HQ | Locations Palo Alto, US HQ |
Employees | Employees 20 | Employees 1633% increase | Employees 24863% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 256 m | Valuation ($) 4.6 b |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $294.3m (FY, 2025) | Revenue (est.) $502.1m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $19.6m (FY, 2025) | Cost of goods $21m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $274.7m (FY, 2025) | Gross profit $481.1m (FY, 2025) |
Net income | Net income N/A | Net income $367m (FY, 2025) | Net income ($732.9m) (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 60m | Total funding raised $ 130m | Total funding raised $ 474.2m |
Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
View company
BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.
View company